Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. ZVRA a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C (NPC) to…#celebration #fla #zevratherapeuticsinc #newdrugapplication #nda #npc #fda #pdufa #zevra #neilmcfarlane
Source: Reuters: Health - Category: Consumer Health News Source Type: news